Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 66

Results For "Development"

3674 News Found

Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women
Clinical Trials | October 29, 2025

Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women

Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women


Orion secures license to Abzena’s next-generation cancer antibody
R&D | October 29, 2025

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,


Novartis completes acquisition of Tourmaline Bio
News | October 29, 2025

Novartis completes acquisition of Tourmaline Bio

Tourmaline is now an indirect wholly owned subsidiary of Novartis


Sai Life Sciences to double process R&D capacity with new facility in Hyderabad
R&D | October 28, 2025

Sai Life Sciences to double process R&D capacity with new facility in Hyderabad

The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization


MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies
R&D | October 28, 2025

MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies

Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies


ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission
R&D | October 27, 2025

ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Mission

With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market


Novartis to acquire Avidity Biosciences for $12 billion
Biotech | October 27, 2025

Novartis to acquire Avidity Biosciences for $12 billion

The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company


GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million
Biotech | October 27, 2025

GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million

Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile


Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion
News | October 27, 2025

Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion

The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year


Lilly buys Adverum for its phase 3-stage eye disease gene therapy
Biotech | October 27, 2025

Lilly buys Adverum for its phase 3-stage eye disease gene therapy

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose